Better Living Peptides
BLP RESEARCH HUBResearch. Regeneration. Results.

MUSCLE, GROWTH & RECOVERYSLEEP, STRESS & CALM

Ipamorelin/CJC-1295

A blend of two peptides acting on two different receptors to amplify the body's own pulsatile growth-hormone release, studied for recovery, sleep, and body composition.

This research blend pairs two peptides that raise growth hormone through different receptors: Ipamorelin, a ghrelin-receptor (GHS-R1a) agonist that triggers a clean GH pulse, and CJC-1295 without DAC, a short-acting GHRH analog that amplifies that pulse. Together they are studied for training recovery, sleep quality, and body composition, and the combination has a long, widespread research-use history.

GHRP + GHRH BlendRecoveryDeep SleepBody Composition

Why BLP features Ipamorelin/CJC-1295

Included because it combines a well-characterized dual GH-release mechanism with one of the longest and most consistent research-use histories among GH-axis peptides. Human trial evidence on the specific blend is limited, but its established use and mechanistic clarity make it a research staple.

Mechanism

Ipamorelin triggers a natural pulse of growth hormone through the ghrelin receptor (GHS-R1a), without the cortisol or prolactin spikes seen with older compounds in its class. Its half-life is roughly 2 hours.

CJC-1295 without DAC is a short-acting GHRH analog: its half-life is roughly 30 minutes and the GH pulse it produces lasts about 1–2 hours. It is the short-acting form, not the long-acting DAC version.

Because the two act through different receptors, the stack amplifies GH pulse amplitude—and pulse frequency if dosed more than once—rather than extending a single release for hours. It is described as producing a larger pulse than either peptide achieves alone.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

  • Human trials on this specific blend are limited. The component peptides are well characterized individually, and the synergy is modeled from their combined pharmacology; no controlled muscle-growth or body-composition trial exists for the combination.
  • Reported research-use observations (not controlled blend-trial endpoints): faster training recovery, deeper sleep, and improved morning energy.
  • Reported research-use observations: changes in body composition, including abdominal fat.
  • Reported IGF-1 elevation within the normal physiological range. Side effects were very mild—occasional water retention or flushing at higher doses.

Preclinical findings

  • Individual GHRP and GHRH mechanisms are well characterized.
  • Synergistic GH-pulse amplification modeled from the combined pharmacology.

Regulatory status

The individual peptides are investigational; the blend is offered strictly for laboratory and research use and is not FDA-approved.

Related research

SermorelinTesamorelinIGF-1 LR3Evidence FrameworkResearch Library